Delenex completes its management team

Thomas Jung becomes chief medical officer

Swiss firm Delenex Therapeutics has appointed Thomas Jung as its chief medical officer.

A board certified dermatologist, Jung has led research work in immunology at the Novartis Research Institute in Vienna, Austria, then spent nine years at Novartis in Basel, Switzerland.

In January 2008 he took leadership of the Ilaris development team, until its first marketing approval in 2009. Since then, he was part of the senior leadership team at the Novartis Institute for Biomedical Research (NIBR), most recently as EU Head of Translational Medicine.

Delenex was created in September 2009 as a spin-off from ESBATech (now part of Alcon, the eye care division of Novartis), and is the exclusive licensee for any non-ophthalmic uses of ESBATech's products and IPR pre-dating the spin-off.

Eric de La Fortelle, ceo of Delenex, said: ‘With the arrival of an experienced clinician, initially trained in dermatology but with significant clinical development experience in several other therapeutic areas, notably autoimmunity, gastroenterology, respiratory, neurosciences and musculoskeletal disorders, Delenex is able to do full justice to its powerful discovery platform, and implement the best clinical programmes to bring its major new compounds to clinical proof of concept.’

You may also like

Manufacturing

Sapio Sciences and Ultima Genomics to work together in advancing multiomics research

The partnership delivers global, end-to-end solutions aimed at making genomics research more streamlined and accessible
Cell & Gene Therapy

Cytiva and WhiteLab Genomics team up to use AI to accelerate cell line development

Collaboration will accelerate stable cell line development in AAV genomic medicine development and ultimately also shorten the development timeline to clinic
Manufacturing

Watson-Marlow to showcase new Bredel CIP pump and innovative fluid handling solutions at PPMA

Watson-Marlow Fluid Technology Solutions (WMFTS) will unveil the new Bredel CIP pump as well as highlight its advanced fluid management technologies during PPMA at the NEC in Birmingham, UK, from 23-25 September 2025
Manufacturing

Evonik and Ethris partner to develop novel lipid nanoparticle platform for nucleic acid delivery

The partnership will enable Evonik to bring more stable and targeted nucleic acid therapies and vaccines to market
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Manufacturing

LGC Group opens $100m Organic Chemistry Synthesis Centre of Excellence in Ontario

The new facility in Vaughn is one of the largest of its kind in the world and will ship to more than 170 countries
Manufacturing

IMA Active to showcase its new tablet presses at NEXTEN in Italy

The event, set at Villa Erba, will celebrate tableting innovation and involve leaders in the pharmaceutical industry through a variety of technical sessions
Subscribe now